RHYTHM PHARMACEUTICALS, INC.
RYTM · XNASCIK 1649904fmd_0RBMTW2PFZ4B7PMT0QADRVK0A9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 44 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 3 | 24 | 77 | 130 | 190 |
| Cost of revenue | – | – | – | – | – | 1 | 2 | 9 | 13 | 19 |
| Gross profit | – | – | – | – | – | 3 | 22 | 68 | 117 | 170 |
| Research and development | 20 | 23 | 50 | 109 | 90 | 104 | 109 | 135 | 238 | 167 |
| Selling, general and administrative | 6 | 10 | 28 | 37 | 46 | 68 | 92 | 118 | 144 | 195 |
| Compensation and benefits | 3 | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 26 | 32 | 78 | 146 | 137 | – | – | – | – | – |
| Operating income | (26) | (32) | (78) | (146) | (137) | (170) | (179) | (184) | (266) | (192) |
| Interest expense | – | – | – | – | – | – | 5 | 14 | 21 | 21 |
| Interest and investment income | 0 | 1 | 4 | 5 | 3 | 0 | – | – | – | – |
| Other non-operating income (expense) | 0 | (1) | 4 | 5 | 3 | 100 | (2) | 0 | 5 | (4) |
| Income before taxes | – | – | – | – | – | (70) | (181) | (184) | (260) | (196) |
| Income tax expense | – | – | – | – | – | – | – | 1 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (185) | (261) | (197) |
| Net income | (26) | (34) | (74) | (141) | (134) | (70) | (181) | (185) | (261) | (197) |
| Net income to common shareholders | (29) | (38) | (74) | (141) | (134) | – | (181) | (185) | (265) | (202) |